| 1 |
Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies |
|
| | Boyuan Huang, Jin Zhang, Wenjing Zong, Sisi Chen, Zhitao Zong, Xiaojun Zeng, Hongbo Zhang | | | Frontiers in Immunology. 2023; 14 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance |
|
| | Sabbir Khan,Sandeep Mittal,Kain McGee,Kristin D. Alfaro-Munoz,Nazanin Majd,Veerakumar Balasubramaniyan,John F. de Groot | | | International Journal of Molecular Sciences. 2020; 21(6): 1954 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma |
|
| | Seidu A. Richard,Wen-Jun Tu | | | Disease Markers. 2020; 2020: 1 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
MiR-146b-5p suppresses the malignancy of GSC/MSC fusion cells by targeting SMARCA5 |
|
| | Haiyang Wang,Liping Tan,Xuchen Dong,Liang Liu,Qianqian Jiang,Haoran Li,Jia Shi,Xuejun Yang,Xingliang Dai,Zhiyuan Qian,Jun Dong | | | Aging. 2020; 12(13): 13647 | | | [Pubmed] [Google Scholar] [DOI] | |
|
